On February 7, 2022 US West Coast Time, Systimmune Inc., an American subsidiary of Biokin Pharmaceuticals announced the appointment of Dr. Martin Sebastian Olivo as Chief Medical Officer (CMO), taking charge of global clinical strategy and development of the Company in tumor pipelines. Dr. Martin Olivo has decades of experience in oncology clinical research and global drug development, who once served as Chief Medical Officer of Protara Therapeutics, and led the company’s early clinical work in the field of non-muscle-invasive bladder cancer.
Dr. Martín Sebastian Olivo
Dr. Zhu Yi, Chairman and Chief Science Officer of Biokin Pharmaceuticals and CEO of SystImmune Inc. said, "We are honored to welcome Dr. Martin Olivo to join our team and take charge of Clinical Development Department of SystImmune Inc. With the orderly development of our multiple clinical trials of anti-tumor drugs, Dr. Martin Olivo will give full play to his expertise in clinical development of anti-tumor drugs to further accelerate the Company's internationalized process and play a key role in advancing the global clinical layout of our R&D pipelines.”
Dr. Martin Olivo said, "I am very luck that I can join the team when SystImmune Inc. is in a critical phase of clinical trial. SystImmune Inc. has multiple world-leading R&D pipelines of anti-tumor drugs, and has a great potential to bring more possibilities to the treatment of difficult cancers. I also look forward to working together with the company’s excellent talents to jointly advance the transformative therapies for cancer treatment and bring hope to tumor patients."
Prior to joining Protara, from August 2018 to April 2021, Dr. Martin Olivo once served as Vice President of Clinical Development Department at Gilead Sciences (formerly known as Immunomedics, Inc. prior to its acquisition) and took charge of clinical development of therapies for advanced breast cancer disease. From July 2017 to July 2018, Dr. Martin Olivo served as Global Clinical Lead of Daiichi Sankyo Cancer Enterprise and developed an effective and comprehensive clinical development program for the company, driving the company’s IND application for U3-1402 (Her3 ADC) drugs in the United States. Prior to that, Dr. Martin Olivo also held several clinical key positions at Eisai.
Dr. Martin Olivo graduated from the University of Buenos Aires with a Ｍaster's degree in Clinical and Pharmacological Research, followed by a Doctor’s degree in Medical Science from the Austral University. Dr. Martin Olive completed his professional training in clinical oncology at of the University of Salvador, and participated in multiple clinical trials and academic research and held key positions at the Medical School of University of Buenos Aires, Dr. Enrique Tornú Hospital and the National Cancer Institute of Canada Clinical Trials Group.
About SystImmune Inc.
Found in 2014, located in Redmond, Washington, Systimmune Inc. is a tumor immunity biotechnology company in clinical trial stage, specializing in the development of bispecific, multi-specific antibody therapies and antibody drug conjugates (ADCs). SystImmune Inc. has several exclusive patent technology platforms based on mutispecific antibodies, including immune cell binding antibody, immune checkpoint inhibitor and tumor growth inhibitor therapies. In addition, SystImmune Inc. has also developed first-class R&D platforms of bispecific ADC drugs. Currently, the company has seven molecular drugs in Phase I or Phase II clinical trial in China, including SI-B001, SI-B003, SI-F019, GNC-038, GNC-039, GNC-035, and BL-B01D1.
